LGND vs INVA

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus 18. 5% for Innoviva, Inc. (INVA). Innoviva, Inc. (INVA) offers the better valuation at 6. 8x trailing P/E (11. 8x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Innoviva, Inc.

is actually cheaper at 11. 8x.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +95. 5%, compared to +83. 9% for Ligand Pharmaceuticals Incorporated (LGND). Over 10 years, the gap is even starker: LGND returned +95. 1% versus INVA's +90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Ligand Pharmaceuticals Incorporated's 0. 99β — meaning LGND is approximately 686% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus 18. 5% for Innoviva, Inc. (INVA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -2. 4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -13. 5% for LGND. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 8x forward P/E versus 26. 1x for Ligand Pharmaceuticals Incorporated — 14. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 67. 3% to $37. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +90. 5%, LGND: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.